Pharma Manufacturing: Attaining the Right Global Mix

Overview


Pharma-Manufacturing-Attaining-the-Right-Global-Mix.jpg

The COVID-19 pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links & re-igniting discussions around the value of reshoring production. The U.S. FDA reports 72% of facilities manufacturing APIs for American drugs are overseas, with 13% in China. Download our white paper where we discuss effective strategies to secure and de-risk pharmaceutical supply chains & reveal how AMRI assures the continual production of urgently needed drugs.

This content is provided by Curia, and any views and opinions expressed do not necessarily reflect those of Outsourcing-Pharma.com

Download Now


Related Resources

Flexibility and capability in pre-filled syringes

Flexibility and capability in pre-filled syringes

Content provided by Curia

White Paper

Pre-filled syringes have risen in popularity in recent years but the pandemic’s impact on drug development, manufacturing and patient care has created new fertile ground for acceleration of adoption that shows no sign of stopping.

Supplier Info Centre

Curia.jpg

For more product information visit Curia.